17 March 2020
Visiongain has launched a new pharma report Global Clinical Trial Management System Market.
The Global Market for Clinical Trial Management System is favoured by technological advancements and the rise of e-clinical platforms within clinical research organisations will continue to drive and take on more clinical trial projects. Continued market disruption by multiple industry forces such as advances in medicine, technology, and cost pressures will also allow now point solution vendors to distinguish themselves and their services over platform vendors. This dynamic will support ongoing diversity in the CTMS technology ecosystem even as the benefits of the CTMS platform continue to grow.
The lead analyst of the report commented "The clinical trials management system market is expected to witness a robust growth during the years of forecast owing to the rise in the number of clinical trials, rising investments in CTMS and advancements in technology. Clinical trial technology vendors have taken the pace of consolidating and incorporating technologies and resources into cloud-based e-clinical systems that support many clinical trial processes. Advanced technologies such as AI, better visualisations and analytics are enabling clients to unlock significant efficiencies in R&D. Having said this, many CROs are entering the CTMS space and increasingly developing their own solutions, this has led to talent poaching and increased competition on the market."
Leading companies featured in the report include Parexel Informatics Inc, Oracle, Medpace Holdings. Mednet Solutions, ERT Clinical, DataTRAK Internationals, Inc and many others.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The Macular Degeneration (AMD) and Other Retinal Diseases Drugs market was valued at US$25.29 billion in 2021 and is projected to grow at a CAGR of 7.87% during the forecast period 2022-2032.
25 November 2022
Pharmaceutical Contract Manufacturing Organisations (CMOs) market is projected to grow at a CAGR of 6.9% by 2032.
25 November 2022
The Dermatology CROs market was valued at US$ 5,154.8 million in 2021 and is projected to grow at a CAGR of 8.7% during the forecast period 2022-2032.
23 November 2022
The Direct-to-Patient market was valued at US$38,651 million in 2021 and is projected to grow at a CAGR of 6.1% during the forecast period 2022-2032.